CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Millions, $ in Millions	Total	Cumulative Effect, Period of Adoption, Adjustment	Class A Common Stock Class A Common Stock		Additional Paid-in- Capital	Retained Earnings	Retained Earnings Cumulative Effect, Period of Adoption, Adjustment	Treasury Stock, at Cost	Accumulated Other Comprehensive Loss
Beginning balance at Dec. 31, 2019	$ 703	$ (15)	$ 5		$ 5,800	$ 9,644	$ (15)	$ (14,385)	$ (361)
Beginning balance (in shares) at Dec. 31, 2019			324.0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(267)					(267)
Other comprehensive income (loss)	226								226
Dividends	(156)					(156)
Stock-based compensation plans (in shares)			1.4
Stock-based compensation plans	89				51			38
Purchase of treasury stock	(150)							(150)
Purchase of treasury stock (in shares)			(1.0)
Ending balance at Dec. 31, 2020	430		$ 5		5,851	9,206		(14,497)	(135)
Ending balance (in shares) at Dec. 31, 2020			324.4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	1,099					1,099
Other comprehensive income (loss)	(207)								(207)
Stock-based compensation plans (in shares)			1.9
Stock-based compensation plans	92				41			51
Ending balance at Dec. 31, 2021	1,414		$ 5		5,892	10,305		(14,446)	(342)
Ending balance (in shares) at Dec. 31, 2021			326.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	2,358					2,358
Other comprehensive income (loss)	(387)								(387)
Dividends	(321)					(321)
Stock-based compensation plans (in shares)			1.1
Stock-based compensation plans	104				73			31
Purchase of treasury stock	(2,600)							(2,600)
Purchase of treasury stock (in shares)			(16.8)
Ending balance at Dec. 31, 2022	$ 568		$ 5		$ 5,965	$ 12,342		$ (17,015)	$ (729)
Ending balance (in shares) at Dec. 31, 2022	310.6		310.6	[1]

[1] Our restated certificate of incorporation authorizes 800 million shares of our common stock, with a par value of $0.01 per share and 10 million shares of preferred stock, without par value. At year-end 2022, we had 310.6 million of these authorized shares of our common stock and no preferred stock outstanding.